If there was an argument, it’s over. Prostate RT is new SOC for men with low volume (≤4 bone mets) metastatic hormone sensitive disease. 7% absolute survival benefit at 3 years. If this was a new drug, the stock price would have rocketed #pcsm #radonchttps://www.europeanurology.com/action/showFullTextImages?pii=S0302-2838%2819%2930111-3 …
Are there capacity constraints in delivering this? How many patients UK wide pa are we talking who are suitable for this?
-
-
Shouldn’t be capacity issues. Most UK centres will use 36Gy in 6 fractions over 6 weeks. We are entering era of extreme hypofractionation & SBRT to many tumour sites, so should be plenty of linnac capacity. Bigger issue is physics/dosimetry capacity, but class solutions help too
-
class solutions?
Einde van gesprek
Nieuw gesprek -
Het laden lijkt wat langer te duren.
Twitter is mogelijk overbelast of ondervindt een tijdelijke onderbreking. Probeer het opnieuw of bekijk de Twitter-status voor meer informatie.